|
IntraVantage
is a developer and marketer of intraosseous drug
delivery technology (intraosseous means “within the
bone”). The first, fully-developed, FDA-approved product,
released in 2003 for distribution in the United States, is
targeted to the dental market (over 324 million
injections/year by 160,000 dentists in the U.S. alone). As
a broader drug delivery platform, applications of intraosseous
delivery are appropriate in a variety of direct situations
(e.g., bone marrow) or situations wherein “traditional”
delivery mechanisms are inadequate, ineffective, or less
desirable (e.g., the cardiovascular system is compromised or
traditional-delivery, side-effects are undesirable). Further,
developments in biotechnology are demonstrating the need for
alternative delivery mechanisms to improve, or even enable,
efficacy. The range of applications includes: orthopedic,
pediatric, neurosurgical, chemotherapy,
bone marrow harvest/biopsy/injection, emergency medicine,
stem cell harvest/injection, and veterinary. To
date, two drug-delivery-related patents have been issued
by the USPTO with international patents pending.
www.intravantageinc.com
MR Instruments' patented RF coil
technology for magnetic resonance imaging creates a better
image, more applications, lowers costs and improves patient
outcomes. An experienced and focused management team has
implemented growth strategies that created revenue, attracted
top talent and quickly moved to commercialize the first
products.
www.mrinstruments.com
Dave Stassen is a founding Managing
Director of
Split Rock Partners and a member of the firm’s health care
investment team. While his investing purview spans the country, Stassen
focuses particularly on the strong medical technology industry in Minnesota.
Prior to founding Split Rock Partners, Stassen was a General Partner with
St. Paul Venture Capital’s health care team. He rejoined St. Paul Venture
Capital in 2000, nine years after he left the firm to lead Spine-Tech, an
emerging growth company specializing in development and marketing of
revolutionary spinal implant products. Stassen led Spine-Tech from its
formation in 1991 through product development, clinical trials, FDA
approval, market launch and growth in revenue to over $100 million. The
company was acquired in January 1998 for over $600 million. In
acknowledgement of this success, Stassen was named the 1998 Ernst & Young
National Entrepreneur of the Year. From 1980 to 1990, Stassen was a
venture capitalist with North Star Ventures, an early-stage venture capital
firm based in Minneapolis. Stassen began his business career with IBM
Corporation, after graduating from the University of St. Thomas in St. Paul,
Minnesota.
www.splitrockpartners.com
Medisyn Technologies
has validated an in silico technology platform that is capable of quickly
designing new or improved drugs from pre-specified properties. Completed
customer projects, published journal articles and in vivo test results for
over 30 different Medisyn designed drug leads validate Medisyn's platform.
Medisyn's first lung cancer candidate, MT103 has demonstrated therapeutic
equivalence to Cisplatin (with an improved toxicity profile) in an in vivo
lung cancer model. Funding to take MT103 into human trials is the next
milestone for the company.
www.medisyntech.com
|
...
by Matt Noah
